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MicroRNAs (miRNAs) have been linked to the molecular pathogenesis of many cancers. In this study,
we found that miR-219-5p was signiﬁcantly downregulated in 83 HCC tissues and three HCC cell
lines, compared to their non-tumor counterparts. MiR-219-5p expression correlated with tumor
size, histological differentiation, and overall survival time in HCC patients. We also found that
miR-219-5p could inhibit cell proliferation in vitro and arrest cell cycle at the G1 to S transition. Fur-
ther studies identiﬁed that miR-219-5p reduced both the mRNA and protein levels of glypican-3
(GPC3). These ﬁndings indicate that miR-219-5p exerts tumor-suppressive effects in hepatic carcino-
genesis through negative regulation of GPC3 expression.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction processes, such as the proliferation, differentiation, and apoptosisHepatocellular carcinoma (HCC), a common primary liver cancer
with high incidences of tumor recurrence and metastasis, is ranked
as the thirdmost common cause of cancer-related deathworldwide
[1]. As with other cancers, the development of HCC is a multistep
process with a variety of changes in gene expression and structure.
In recent years, a newclass of regulatoryRNAs, themicroRNAs (miR-
NAs), has been discovered. Aberrant microRNA expression has been
linked to the molecular pathogenesis of HCC [2].
MiRNAs negatively regulate gene expression by binding to the
30 untranslated region (30UTR) of corresponding target messenger
RNAs (mRNAs) [3]. Emerging evidence has recently shown that
several miRNAs play an important role in various biologicalchemical Societies. Published by E
iRNA, microRNA; 30UTR, 30
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. Zheng), luorc01@163.comof human cancers [3,4]. The alteration of miRNA expression is ob-
served in HCCs and has been linked to the molecular pathogenesis
of HCCs through their ability to impact the expression of crucial
mRNAs. Depending on the target gene, miRNAs can function as tu-
mor suppressor genes or oncogenes. For instance, it has been found
that miR-22, miR-29c, miR-101, miR-122a, miR-124, miR-125b,
miR-142-3p, miR-519d, and miR-637, which regulate the expres-
sion of many genes, are downregulated during HCC carcinogenesis
and progression [5–13]. MiR-375 targets AEG-1 and inhibits HCC
cell growth, and miR-519d suppresses HCC cell growth by target-
ing the MKi67 [12,14]. In addition, miR-122 is frequently downreg-
ulated in HCC and sensitizes HCC cells to adriamycin and
vincristine by modulating the expression of multidrug resistance
and inducing cell cycle arrest [15]. In contrast, other miRNAs, such
as miR-29a, miR-191, miR-221, and miR-199a-3p, are often upreg-
ulated and found to function as oncogenes in HCC [16–18]. It has
been found that inhibition of miR-191 can decrease cell prolifera-
tion and induced apoptosis [17]. MiR-221 can stimulate tumor
growth via p27 and DDIT4 down-regulation [19]. In summary, dys-
regulation of miRNAs is involved in hepatocarcinogenesis. There-
fore, identiﬁcation of cancer-speciﬁc miRNAs and their targets is
critical to understand their role in tumorigenesis and might be
important for deﬁning novel therapeutic targets [20,21]. Recently,
miR-219 was found to be downregulated in squamous celllsevier B.V. All rights reserved.
Table 1
Correlations between miR-219-5p and various clinicopathological characteristics of HCC.
Features MiR-219-5p P
Downregulation (%) Normal/upregulation (%)
Gender Male 45 (60.8) 29 (39.2) 1.000a
Female 6 (66.7) 3 (33.3)
Age (years) <60 41 (65.1) 22 (34.9) 0.227
P60 10 (50.0) 10 (50.0)
Serum HBsAg Normal 8 (57.1) 6 (42.9) 0.717
Overexpression 43 (62.3) 26 (37.7)
Serum AFP Negative 17 (60.7) 11 (39.3) 0.922
Positive 34 (61.8) 21 (38.2)
Tumor size-diameter of the biggest nodule <5 cm 12 (44.4) 15 (55.6) 0.027*
P5 cm 39 (69.6) 17 (30.4)
Histological differentiation Well/moderately 35 (54.7) 29 (45.3) 0.030*,a
Poorly 16 (84.2) 3 (15.8)
Hepatic cirrhosis No 12 (54.5) 10 (45.5) 0.438
Yes 39 (63.9) 22 (36.1)
TNM staging I-II 28 (54.9) 23 (45.1) 0.122
III-IV 23 (71.9) 9 (28.1)
* P < 0.05.
a Two-sided Fisher’s exact test.
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the repression of miR-219 in potentially cancerous lung tissue
[24]. Microarray analysis has shown that miR-219 is commonly
downregulated in hepatitis B virus (HBV) and hepatitis C virus
(HCV)-related diseases [25]. However, the molecular mechanism
of miR-219 in HCC remains unclear. In this study, we focused on
the expression and function of miR-219 in HCC.
This study, we found the expression of miR-219-5p to be down-
regulated in HCC tissues, and the level of expression was found to
be related to tumor size, histological differentiation, and overall
survival time of HCC patients. Further investigation revealed that,
miR-219-5p may function as a tumor suppressor through nega-
tively regulates of glypican-3 (GPC3).
2. Materials and methods
2.1. Patients and tissue samples
Eighty-three pairs of primary HCC and corresponding non-tu-
mor adjacent tissue samples from patients were obtained from
Nanfang Hospital with patients0 informed consent. The study was
approved by our Research Ethics Committee.
2.2. Cell lines and transfection
Human HCC cell lines Huh-7, MHCC-97H, MHCC-97L, HepG2,
HCCLM6 and the human hepatocyte cell line HL-7702 were propa-
gated in DMEM (Gibco-BRL) supplemented with 10% fetal bovine
serum. The cells were maintained at 37 C in an atmosphere of
humidiﬁed air with 5% CO2.
Transfection was performed with Lipofectamine 2000 Reagent
(Invitrogen, CA, U.S.) according to the manufacturer instructions.
MiR-219-5p mimics, mimics negative controls (m-NCs), miR-219-
5p inhibitor and inhibitor negative controls (i-NCs) were pur-
chased from Ribobio (Guangzhou, China). A ﬁnal concentration of
50 nM of mimics or 100 nM of inhibitor and their respective nega-
tive controls were used for each transfection in proliferation, cell
cycle and apoptosis experiments.
2.3. RNA extraction and quantitative reverse transcription-polymerase
chain reaction (qRT-PCR)
Total RNAwas extracted from tissue samples and cell lines using
TRIzol reagent (Invitrogen) according to the manufacturer’sinstructions. For the detection of mature miRNA, we performed a
stem-loop qRT-PCR assay. One microgram RNA was resuspended
in 12 ll RNase-free ddH2O and incubated at 85 C for 5 min and then
chilled on ice. Reverse transcription was carried out by adding 1 ll
speciﬁc stem-loop RT primers (Applied Land, Guangzhou, China)
and7 llM-MLVRT reagent containing2 ll of 10 mMdNTPMix (Pro-
mega, Madison, WI, U.S.), 0.5 ll RNase inhibitor (Promega), 4 ll
5  buffer (Promega), and 0.5 ll M-MLV (Promega). The ﬁnal vol-
ume was 20 ll in total. The reaction mixture was incubated at
42 C for 60 min, at 85 C for 10 min and then held at 4 C. The cDNA
was ampliﬁed using SYBR Green PCR Master Mix (Toyobo, Osaka,
Japan). The 20 ll PCR reaction mixture included 5 ll cDNA (1:20
dilution), 10 ll 2  SYBR Green PCR Master Mix (Toyobo), 0.5 ll
forward primer, 0.5 ll reverse primer, and 4 ll RNase-free ddH2O.
Primers are listed in Supplementary Table 1. PCR reactionswereper-
formed under the following conditions: an initial denaturation step
(95 C for 5 min), 40 cycles of 95 C for 15 s, 65 C for 15 s and 72 C
32 s. In brief, detection of the relative transcript levels of GPC3 was
performed using qRT-PCR, an All-in-One™ First-Strand cDNA Syn-
thesis kit (GeneCopoeia™, Guangzhou, China), and an All-in-One™
qPCRMix (GeneCopoeia™) according to themanufacturers’ instruc-
tions. Human GPC3 primer and GAPDH primer were acquired from
GeneCopoeia™. The PCR cycles were as follow: 95 C for 10 min fol-
lowed by 40 cycles of 95 C for 10 s, 60 C for 20 s and 72 C for 15 s.
The mean cycle threshold (Ct) was determined by triplicate PCR
runs, and the relative expression was normalized to that of internal
control snRNA U6 or GAPDH and calculated using 2DDCt method
[26]. Changes in the expression of HCC were found to be relative
to the non-tumorous controls (HL-7702 cells and non-tumorous
tissue adjacent to tumors). Therefore, the value of the relative
expression ratio < 1.0 was taken to indicate downregulation in
cancer relative to the non-tumorous control, and the ratio > 1.0
was considered as normal/upregulation [27].
2.4. Cell proliferation assay
The cell proliferation was determined by WST-8 staining with a
Cell Counting Kit-8 (CCK-8) (Beyotime, Shanghai, China) according
to the manufacturer’s instructions. 5000 cells were seeded in 96-
well plates and transfected with miR-219-5p mimics or m-NCs
the next day. CCK-8 solution was used to measure cell viability
at 48 h after transfection. The absorbance of each well was mea-
sured with a microplate reader set at 450 nM. All experiments
were performed in triplicate.
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Two hundred cells were counted and plated onto 12-well plates
after transfection. Fresh culture medium was replaced every
3 days, and colonies were counted 14 days after plating. The cells
were stained with crystal violet. The number of colonies containing
more than 50 cells was determined under a microscope, as previ-
ously described [28]. All experiments were performed in triplicate.
2.6. Cell cycle analysis and apoptosis assay
For cell cycle analysis, 48 h after transfection, the adhered cells
were obtained and ﬁxed into 70% ethanol at 4 C. After 12 h, propi-
dium iodide (PI) and RNase A were added to the cells according to
manufactures’ instructions (Beyotime, Shanghai, China). Samples
were analyzed 30 min after staining with use of ﬂow cytometry-
BD FACSCalibur (BD Bioscience, MA, U.S.). Results were analyzed
using CellQuest software (BD Biosciences). For the apoptosis assay,
48 h after transfection, cells were resuspended in binding buffer
containing annexin V-FITC and PI according to the manufacturers’
instructions (BD Bioscience). Samples were assessed using ﬂow
cytometry as described above. Each sample was run in triplicate.
2.7. Dual-luciferase reporter assay
The dual-luciferase reporter plasmid psi-CHECK2-wGPC3 (con-
taining the wild-type GPC3 putative 30UTR binding site) and psi-
CHECK2-mGPC3 (contained mutant GPC3 30UTR) was constructed
by LAND. HEK-293T cells were plated into 24-well plates with
50–60% conﬂuence 24 h before transfection. A mixture of 50 nM
miR-219-5p mimics and 0.5 lg psi-CHECK2 report plasmid was
cotransfected into cells using Lipofectamine 2000 reagent. After
48 h, luciferase activity levels were measured using a dual-lucifer-
ase reporter assay system (Promega) according to the manufactur-
ers’ instructions. Each transfection was performed in triplicate.
2.8. Western blot
Whole cell protein extracts were quantiﬁed by BCA assay and
then resolved on a 6% SDS polyacrylamide gel (Invitrogen). They
were then transferred onto a nitrocellulose membranes (Bio-Rad)
and then blocked in 5% skim milk in TBST, incubated with anti-
GPC3 antibody (Abcam, HongKong) or anti-GAPDH antibody over-
night at 4 C. Signals were revealed after incubation with anti-rab-
bit IgG secondary antibody coupled to peroxidase by using ECL.
2.9. Immunohistochemical (IHC) and staining evaluation
IHC was performed in 45 HCC tissues samples according to the
methods that had been used in previous studies [29].
2.10. Statistical analysis
All statistical analyses were performed using SPSS13.0 for Win-
dows (SPSS Inc., Chicago, IL, U.S.). P < 0.05 was considered statisti-
cally signiﬁcant.3. Results
3.1. Expression of miR-219-5p and its correlation with
clinicopathological characteristics of HCC
In this study, we sought to conﬁrm that miR-219-5p was down-
regulated in primary HCC. Using qRT-PCR, the expression levels of
miR-219-5p in all 83 (100%) pairs of HCC tissues, their matchednon-tumor adjacent tissues, and the HCC cell lines were deter-
mined and normalized against an endogenous control, snRNA U6.
We found miR-219-5p to be signiﬁcantly downregulated in HCC
samples (P < 0.01). The median miR-219-5p expression level in
HCC tissues was four times lower than that of the non-tumor adja-
cent tissues (median expression 0.088 and 0.384, respectively)
(Fig. 1A). Among the 83 patients with primary HCC, 51 (61.45%)
showed a reduction in the miR-219-5p level of over 50% relative
to their matched non-tumor adjacent tissues (Fig. 1B). We then
studied the correlation between miR-219-5p expression and the
clinicopathological characteristics of HCC. The patients with lower
levels of miR-219-5p expression tended to have larger tumor sizes
(P5 cm; P = 0.027) and poor differentiation (P = 0.030; Table 1).
Kaplan–Meier analysis also showed that downregulation of miR-
219-5p was associated with decreased survival (Fig. 1C). Speciﬁ-
cally, the median overall survival time was 13.0 and 30.0 months
in miR-219-5p downregulation and normal/upregulation groups,
respectively (P = 0.005, log-rank test).
We also found that, compared to normal liver cell line HL-7702,
miR-219-5p was downregulated in all HCC cell lines: (Huh-7,
0.06 ± 0.02-fold; MHCC-97H, 0.57 ± 0.12-fold; MHCC-97L,
0.74 ± 0.07-fold; HepG2, 0.11 ± 0.02-fold; HCCLM6, 0.14 ± 0.02-
fold; Fig. 1D).
3.2. Effects of miR-219-5p on HCC cell proliferation in vitro
The downregulated miR-219-5p in HCC prompted us to investi-
gate whether miR-219-5p functions as a tumor suppressor. In HCC
cell lines Huh-7 and HepG2, we found miR-219-5p expression was
markedly decreased (Fig. 1C), and restoration of miR-219-5p
expression by miR-219-5p mimics inhibited cell proliferation in
Huh-7 and HepG2 cells (Fig. S1A and Fig. 2A). To provide further
evidence that miR-219-5p is involved in HCC cell growth, we se-
lected the HCC cell line MHCC-97L, which has a relatively high le-
vel of miR-219-5p (Fig. 1C), and studied the effects of an inhibitor
of miR-219-5p. In contrast, proliferation of MHCC-97L cells trans-
fected with miR-219-5p inhibitors was found to be higher than
that of the cells transfected with i-NCs (Fig. S1B and Fig. 2B). Col-
ony formation assay showed that enforced expression of miR-
219-5p resulted in a decrease of more than 20% in the number of
colonies in HepG2 cells (Fig. 2C). Transfection of miR-219-5p inhib-
itors into MHCC-97L cells signiﬁcantly increased the number of
colonies when relative to i-NCs (Fig. 2D).
3.3. Effects of miR-219-5p on cell cycle in HCC cells
Given thatmiR-219-5pobviously inhibitedHCCcell proliferation
in vitro, we next sought to determine whether miR-219-5p would
have any impact on cell cycle progression among HCC cells. The cell
cycle distribution of HepG2 cells showed that the number of cells in
theG1phasewas greater in cells transfectedwithmiR-219-5pmim-
ics than in m-NCs (P = 0.009). The number of cells in the S phase
droppedsharply (P = 0.018) (Fig. 3A). In contrast, the cell cycledistri-
bution analysis of MHCC-97L cells after transfection of miR-219-5p
inhibitor showed that inhibition of miR-219-5p could increase the
number of cells in the S phase over i-NCs (P < 0.001) (Fig. 3B and
C). We also examined the effects of miR-219-5p on apoptosis. Data
indicated thatmiR-219-5p had no effect on apoptosis inHepG2 cells
at 48 and 72 h after transfection (Fig. S2).
3.4. GPC3 as a direct downstream target of miR-219-5p
Next, we investigated the molecular mechanisms responsible
for the anti-tumor effects of miR-219-5p in the HCC cells observed
above. Because microRNA usually exerts its functions by suppress-
ing the expression of target mRNAs, we searched the putative
Fig. 1. Downregulation of miR-219-5p in human HCCs (A) The expression level of miR-219-5p in HCCs and non-tumor tissues were compared by way of Wilcoxon signed-
rank test. (B) MiR-219-5p expression was examined in 83 pairs of primary HCCs and their corresponding non-tumor tissues by qRT-PCR. Data were presented as log2 of fold
change of HCC relative to non-tumorous adjacent tissues. The cases below the line (log2 = 1) showed a >50% reduction in the miR-219-5p expression level. (C) The
relationship between miR-219-5p expression and overall survival in HCC patients. The survival rate for patients in the miR-219-5p downregulation group (n = 51) was
signiﬁcantly lower than that in the normal/upregulation group (n = 32) (P = 0.005). (D) The relative level of miR-219-5p in HCC cell lines (Huh-7, MHCC-97H, MHCC-97L,
HepG2, and HCCLM6) relative to HL-7702. ⁄P < 0.05; ⁄⁄P < 0.01.
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scan.org/) and miRanda (microrna.org and miRbase). GPC3 was
predicted to be a potential target of miR-219-5p by miRanda
(Fig. 4A). Our previous studies have indicated that GPC3 is com-
monly overexpressed in human HCC, and it directly contributes
to the carcinogenesis and development of HCC by controlling cell
proliferation [28,29]. A putative binding site for miR-219-5p was
found in the 3’UTR of GPC3, so we chose GPC3 for further study.
To verify whether GPC3 is a direct target of miR-219-5p, we con-
structed luciferase reporter plasmid containing either wild-type
or mutant 30UTR of GPC3 (Fig. 4B). The wild-type and mutant plas-
mids were cotransfected into HEK-293T cells with miR-219-5p
mimics or m-NCs. Relative luciferase activities were measured by
a dual-luciferase reporter assay system and normalized by dividing
ﬁreﬂy luciferase activity by that of Renilla luciferase. As shown in
Fig. 4C, the relative luciferase activity in cells cotransfected with
wild-type GPC3 30UTR and miR-219-5p mimics was signiﬁcantly
decreased after 48 h (P = 0.004). The reduction in the luciferase
activity with mutant GPC3 30UTR was not as sharp as that observed
in the wild-type counterpart (P = 0.515), suggesting that miR-219-
5p could directly bind to the 30UTR of human GPC3. We examined
the GPC3 mRNA levels in HepG2 and Huh-7 cells transfected with
miR-219-5p mimics or m-NCs by PCR. Forty-eight hours after
transfection, we found that mRNA level of GPC3 to have been sup-
pressed by miR-219-5p both in HepG2 and Huh-7 cells (P = 0.016
and 0.002, respectively) (Fig. 4D). We found that miR-219-5preduced GPC3 protein levels in HepG2 at 96 h post-transfection
(Fig. 4E). These data suggest that miR-219-5p negatively regulates
GPC3 protein expression through mRNA degradation and transla-
tional repression.
3.5. Inverse correlation between the expression of miR-219-5p and
GPC3 protein in HCC tissue samples
We measured GPC3 protein levels in 45 of the previously stud-
ied 83 HCC tissues using IHC. These samples had already been ver-
iﬁed as expressing miR-219-5p by qRT-PCR. The expression level of
GPC3 protein was deﬁned as normal/underexpression (/+) and
overexpression (++/+++). GPC3 was overexpressed in 30 (66.67%)
cases, and an obvious inverse correlation was observed between
the expression of GPC3 protein and miR-219-5p in HCC tissue sam-
ples (P = 0.034) (Table 2). The correlation coefﬁcient was not per-
fect (r = 0.316).
4. Discussion
Recent studies have demonstrated the importance of miRNAs in
human hepatic carcinogenesis [2]. The identiﬁcation of cancer-spe-
ciﬁc miRNAs and their targets is critical to understanding their role
in tumorigenesis. Our present study conﬁrmed that the downregu-
lation of miR-219-5p in 60% of HCC tissues. However, it has been
reported that miR-219 is downregulated in chronic hepatitis (CH)
Fig. 2. MiR-219-5p suppresses HCC cell proliferation in vitro (A) Measurement of cell proliferation by CCK-8 assay. After Huh-7 and HepG2 cells were transfected with miR-
219-5p mimics or m-NCs, the CCK-8 solution was added to determine the relative cell growth activity at 24, 48, and 72 h post-transfection. (B) CCK-8 assay in MHCC-97L cells.
After MHCC-97L cells were transfected with miR-219-5p inhibitors or i-NCs, the CCK-8 assay was used to determine the relative cell growth activity at 24, 48, 72, and 96 h
post-transfection. (C, D) Effects of miR-219-5p on cell proliferation as evaluated by a colony formation assay. HepG2 and MHCC-97L cells were transfected with miR-219-5p
mimics or inhibitor and their respective negative controls. After 14 days of culture, the cells were stained with crystal violet and the colony formation rate was calculated.
Representative pictures of colonies are shown. The histogram shows the mean ± SD of three independent experiments. ⁄P < 0.05; ⁄⁄P < 0.01.
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Fig. 3. Effects of miR-219-5p on cell cycle in HCC cells (A) MiR-219-5p induced G1 arrest in HCC cells. HepG2 cells transfected with miR-219-5p mimics or m-NCs were
analyzed using ﬂuorescence-activated cell sorting. (B, C) Inhibition of miR-219-5p with transfection of miR-219-5p inhibitors promoted the entry of MHCC-97L cells into S
phase. ⁄P < 0.05; ⁄⁄P < 0.01.
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array analysis. This study also reported no difference between CH
and HCC in the expression of miR-219 [25]. Our data showed that
downregulation of miR-219-5p was not signiﬁcantly associated
with HBsAg and hepatic cirrhosis. The non-tumorous adjacent
samples examined in our study included normal liver, CH, and he-
patic cirrhosis tissues. And we found that the expression of miR-
219-3p was not signiﬁcantly different in HCC tissues and non-
tumorous adjacent tissues (data not shown). These can perhaps ex-
plain the discrepancies.
Moreover, the HCC patients who showed low expression levels
of miR-219-5p tended to have larger tumors, poorer differentia-
tion, and shorter survival times, suggesting that miR-219-5p might
participate in HCC progression and negatively control HCC cell
growth.
Previous studies found that miR-219 inhibited cell proliferation
[22,30]. Indeed, our ﬁndings showed that miR-219-5p could signif-
icantly suppress HCC cell proliferation in vitro. Mechanistic insight
into the inhibitory effects of miR-219-5p on cell proliferation indi-
cate that miR-219-5p can induce cell cycle arrest at the G1 to S
transition of HCC cells, suggesting that downregulation of miR-
219-5p in HCC may cause the cancer cells to divide and grow more
quickly. Previous data, in combination with our current ﬁndings,
raise the possibility that loss of miR-219-5p expression may con-
tribute to the aberrant proliferation observed in HCC.Bioinformatics analysis has indicated that GPC3 is a putative
target of miR-219-5p. Dual-luciferase assay, qRT-PCR and Western
blot analysis identiﬁed GPC3 as one of the genes directly targeted
by miR-219-5p. A decrease in miR-219-5p expression was shown
to be inversely correlated with GPC3 protein expression levels in
45 pairs of HCC tissue samples. These results suggest that miR-
219-5p interacts with GPC3 and negatively regulates its expres-
sion. GPC3 is a cell surface protein that has been implicated as a
possible tumor marker for HCC[31]. GPC3 is highly expressed in
HCC and at a lesser degree in melanoma, ovarian clear-cell carcino-
mas, yolk sac tumors, and some other human tumors [31]. Our pre-
vious study indicated that GPC3 might be a valuable marker closely
related with poor outcomes and post-operative metastasis/recur-
rence of HCC [29]. GPC3 plays an important role in cell growth, dif-
ferentiation and metastasis. In 2005, GPC3 was reported to
promote proliferation of HCC cells by stimulating the canonical
Wnt pathway through facilitating the interaction between the
Wnts and their signaling receptors [32]. Our previous study con-
ﬁrmed that knockdown of GPC3 expression signiﬁcantly inhibited
the growth and invasive ability of MHCC-97H cells [28]. We now
propose that miR-219-5p may have an effect on HCC proliferation
by downregulating GPC3. Although it has been demonstrated that
miR-96 downregulated GPC3 expression by targeting its mRNA
30UTR, the mechanism of GPC3 overexpression in HCC has not been
well characterized [33]. In the present study, we found that
Fig. 4. GPC3 as a direct downstream target of miR-219-5p (A) miRanda predicted that miR-219-5p would target the 30UTR of GPC3. (B) Construction of binding site of wild-
type and mutant GPC3 mRNA 30UTR. The mutant binding site is underlined. (C) Relative luciferase activity analyses. The psi-CHECK2, psi-CHECK2-wGPC3, or psi-CHECK2-
mGPC3 was cotransfected into HEK-293T cells with miR-219-5p mimics, m-NCs. (D) The expression level of GPC3 mRNA was down-regulated by miR-219-5p using qRT-PCR
and semi-quantitative PCR assays. (E) Western blot results of GPC3 protein in HepG2 transfected with miR-219-5p mimics or m-NCs at 48 and 96 h. ⁄P < 0.05.
Table 2
Correlation between the expression of miR-219-5p and GPC3 protein in HCC cases MiR-219-5p expression was found to be correlated with GPC3 level. Data was taken from 45
pairs of HCC tissue samples using Spearman correlation. An inverse correlation was observed between miR-219-5p and GPC3 protein expression (P < 0.05, r = 0.316).
GPC3 n MiR-219-5p Spearman’s correlation
Underexpression (No. of cases) Normal/overexpression (No. of cases) P R
Normal/underexpression (/+) 15 5 10 0.034 0.316
Overexpression (++/+++) 30 20 10
890 N. Huang et al. / FEBS Letters 586 (2012) 884–891overexpression of GPC3 in HCC may be caused by the downregula-
tion of miR-219-5p. Although we found an obvious inverse corre-
lation between the expression of GPC3 and miR-219-5p in tissues
samples, the correlation coefﬁcient was not prefect (r = 0.316). It
is worth considering whether other mechanisms may be involved
in the regulation of miR-219-5p. Dugas et al found that miR-219
targets PDGFRa, Sox6, FoxJ3, and ZFP238 to repress oligodendro-cyte precursor cell proliferation and promote oligodendrocyte dif-
ferentiation [30]. In this way, miR-219-5p may regulated several
targets in HCC. This issue merits further investigation.
In conclusion, we have shown that miR-219-5p is downregu-
lated in most cases of HCC and closely associated with larger tumor
size, poorer histological differentiation, and shorter overall survival
time in HCC patients. MiR-219-5p can suppress HCC cell growth
N. Huang et al. / FEBS Letters 586 (2012) 884–891 891and induce cell cycle arrest at the G1 phase. These tumor-suppres-
sive functions of miR-219-5p are mediated by the target gene
GPC3, a new target for HCC immunotherapy. These ﬁndings suggest
that miR-219-5p may have an important role in tumorigenesis
through the regulation of GPC3.
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